These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 27001532)

  • 1. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
    Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
    Tsuji Y; Baba H; Takeda K; Kobayashi M; Oki E; Gotoh M; Yoshida K; Shimokawa M; Kakeji Y; Aiba K
    Expert Opin Pharmacother; 2017 Jun; 18(8):753-758. PubMed ID: 28395603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
    Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS
    Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan.
    Mizuno M; Hiura M; Kikkawa F; Numa F; Yaegashi N; Narahara H; Aoki D; Kimura E; Kato H; Shimokawa M; Sugiyama T; Kamura T
    Gynecol Oncol; 2016 Mar; 140(3):559-64. PubMed ID: 26748216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2017 Apr; 22(2):405-412. PubMed ID: 27909835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
    Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
    Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
    Gilmore JW; Peacock NW; Gu A; Szabo S; Rammage M; Sharpe J; Haislip ST; Perry T; Boozan TL; Meador K; Cao X; Burke TA
    J Oncol Pract; 2014 Jan; 10(1):68-74. PubMed ID: 24065402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
    Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
    Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
    Kottschade L; Novotny P; Lyss A; Mazurczak M; Loprinzi C; Barton D
    Support Care Cancer; 2016 Jun; 24(6):2661-7. PubMed ID: 26768436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study.
    Naito Y; Kai Y; Ishikawa T; Fujita T; Uehara K; Doihara H; Tokunaga S; Shimokawa M; Ito Y; Saeki T
    Breast Cancer; 2020 Jan; 27(1):122-128. PubMed ID: 31407150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
    Iihara H; Shimokawa M; Hayashi T; Kawazoe H; Saeki T; Aiba K; Tamura K
    Oncologist; 2020 Feb; 25(2):e373-e380. PubMed ID: 32043774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
    Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
    J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed.
    Erazo Valle A; Wisniewski T; Figueroa Vadillo JI; Burke TA; Martinez Corona R
    Curr Med Res Opin; 2006 Dec; 22(12):2403-10. PubMed ID: 17257454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy.
    Hu Z; Liang W; Yang Y; Keefe D; Ma Y; Zhao Y; Xue C; Huang Y; Zhao H; Chen L; Chan A; Zhang L
    Medicine (Baltimore); 2016 Jan; 95(2):e2476. PubMed ID: 26765450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis.
    Chow R; Yin LB; Baqri W; Huang R; Boldt G; Younus J; Lock M; Prsic E; Zimmermann C; Herrstedt J
    Support Care Cancer; 2023 Aug; 31(8):505. PubMed ID: 37535218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries.
    Hsieh RK; Chan A; Kim HK; Yu S; Kim JG; Lee MA; Dalén J; Jung H; Liu YP; Burke TA; Keefe DM
    Support Care Cancer; 2015 Jan; 23(1):263-72. PubMed ID: 25120009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.
    Burke TA; Wisniewski T; Ernst FR
    Support Care Cancer; 2011 Jan; 19(1):131-40. PubMed ID: 20101417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group.
    Araz M; Karaagac M; Korkmaz L; Beypinar I; Uysal M
    Curr Probl Cancer; 2019 Aug; 43(4):344-353. PubMed ID: 30497851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.